Although an increasing amount of knowledge is available about the health-related quality of life of patients with chronic spontaneous (idiopathic) urticaria, no health state utilities have been established for this condition. Utilities are key data for economic models used in making reimbursement decisions in many countries.

This paper presents utilities for different levels of disease activity of chronic spontaneous urticaria. This information will be valuable for future cost-effectiveness models. Utilities measured by generic measures, such as the EQ-5D, allow for health-related quality-of-life comparisons between different disease areas.

Evaluation of these utilities provides robust results for health technology assessment bodies to evaluate the cost effectiveness of treatments for chronic spontaneous urticaria and quantification of health gains by calculation of quality-adjusted life-years.